NCT05214677View on ClinicalTrials.gov

A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of DW1809

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

August 15, 2020

Primary Completion Date

September 7, 2020

Study Completion Date

September 7, 2020

Conditions
OsteoarthritisRheumatoid ArthritisBack PainAcute Upper Respiratory Tract Infection
Interventions
DRUG

DW1809

pelubiprofen 30mg

DRUG

DW1809-1

pelubiprofen 30mg (PELUBI tab.)

Trial Locations (1)

Unknown

Chungbuk National University Hospital, Cheongju-si

Sponsors
All Listed Sponsors
lead

Daewon Pharmaceutical Co., Ltd.

INDUSTRY

NCT05214677 - A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of DW1809 | Biotech Hunter | Biotech Hunter